Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients

• Coya Therapeutics Inc (NASDAQ: COYA) reported 48-week clinical data for its proof-of-concept open-label study in 4 Amyotrophic Lateral Sclerosis (ALS) patients indicating that treatment with COYA 302 appeared to ameliorate disease progression.

• During the 48-week treatment period, COYA 302 appeared to be well tolerated.

• Preliminary efficacy of COYA 302 was measured by the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in ALS patients.

• The mean (±SD) ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of COYA 302 treatment were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9), indicating significant amelioration in the progression of the disease over the 48-week treatment period.

• Treg suppressive function, expressed as a percentage of inhibition of proinflammatory T cell proliferation, showed a statistically significant increase over the treatment period and was significantly reduced at the end of the 8-week washout post-treatment period.

• The study also evaluated serum biomarkers of inflammation, oxidative stress, and lipid peroxides.

• The available data up to 16 weeks suggest a decrease of these biomarker levels, which is consistent with the observed enhancement of Treg function.

• The evaluation of the complete biomarker data is ongoing.

• The company said it plans to file an IND with the FDA in the second half of 2023 and initiate a clinical study soon after.

• Price Action: COYA shares are up 4.95% at $4.24 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.